Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$2.78 morning high; who is accumulating here?
Could it be some of these smart money folks or some retail investors other than Sunofwolf.
There was a single 10,000 share purchase of CLRB IN THE OPENING HOUR OF TRADING TODAY.
Cellectar BioSciences Inc, Inst Holders, 4Q 2019 (CLRB)
BY Dow Jones & Company, Inc.
— 3:50 AM ET 01/22/2020
The following table shows the largest shareholders in CELLECTAR BIOSCIENCES INC COM (CLRB) for the quarter ended December 31, 2019, listed by holding size. The list represents up to 50 of the largest holders in the company.
Note: Unless otherwise mentioned the reporting date is 12/31/2019
Institution Shares Shares % Last
Held Changed Held Report
Tavistock Life Sciences Co. (I 920,000 0 9.791 09/30
Tang Capital Management LLC 235,701 (444,299) 2.509 09/30
Renaissance Technologies LLC 176,902 53,854 1.883 09/30
Sphera Funds Management Ltd. 87,500 0 0.931 09/30
Morgan Stanley Smith Barney LL 32,221 (3,000) 0.343 09/30
The Vanguard Group Inc. 16,755 0 0.178 09/30
Private Advisor Group LLC 13,400 0 0.143 09/30
JPMorgan Securities LLC (Inves 10,505 10,505 0.112 09/30
For cheap LEVERAGE: Remember CLRBZ
April 2021 Warrants currently trading at $.15 this am.
CLRBZ 52 week high near one dollar per. Leverage!
CLRBZ before 2-19-20 press release of more clinical trial data.
THERE MUST BE SOME INSIDER INFORMATION BEHIND THE RECENT CLRB ACCUMULATION!!!
CLRB TRADING AT $2.79 pps THIS MORNING, UP ALMOST 5 %
There's something happening here
What it is ain't exactly clear
There's a man with a gun over there
Telling me I got to beware
REMEMBER FEBRUARY 19, 2020 for more clinical trial data.
time for the company to sell out the investor!
another stock reverse can happen at any time destroying your share value-crooks.
Happy Hour open price $2.75 pps,
Calmer heads prevailed on FDA orphan drug news this morning.
https://seekingalpha.com/news/3529761-cellectar-bio-up-11-premarket-on-orphan-drug-tag-for-clr-131-in-lpl?source=cnbc
Crusader, great post.. thank you!! Keep them coming.. I'm also
extremely bullish on the future of CLRB and can't wait for the 19th
next month...
WHere is the BOTTOM LINE of CLRB for MM patients:
Page 10 from the CLRB data presentation in my last post below.
It shows trial result numbers better than CAR-T trials and on-going CLR131 ORR as good and becoming better than MM drugs now being sold when they were at this stage of CLRB’s clinical trials- ON SEVERAL FORM OF CANCER, NOT JUST MM!
The FDA has approved many popular MM drugs such as Pomalyst which had an ORR of just 30% in its clinical trials. ( SEE PAGE 9 of presentation linked below) Now Pomalyst is selling at $17,000 for 21 4mg pills = one month dosing for use with Decadron once a week.
According to page 10 of the presentation ( https://seekingalpha.com/article/4316868-cellectar-biosciences-clrb-presents-biotech-showcase-2020-slideshow?dr=1&source=2800:read_now&utm_medium=email&utm_source=seeking_alpha ) CLR131 has already met and exceeded Pomalyst’s ORR IN CLINICAL TRIALS results (page 9) before Celegene was approved to market Pomalyst.
I BELIEVE CLRB WILL BE BOUGHT OUT (M&A) BY BIG PHARMA WITHIN ONE YEAR FOR REASONS REFLECTED IN LINK ABOVE OF CLRB’s PUBLIC PRESENTATION SCHEDULED FOR 2-19-20.
Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020
BY GlobeNewswire
— 8:00 AM ET 01/09/2020
FLORHAM PARK, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences ( CLRB
), Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it will host a Clinical Data Call on Wednesday, February 19, 2020 at 10:30 am Eastern Time.
WHY HIRE A CHIEF MEDICAL RESEARCH OFFICER
with experience in global drug approval processes? And then this stock goes up in price 10%, more or less and after an announcement of a CLR131 clinical data release is scheduled for 2-19-20?
Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer
BY GlobeNewswire
— 8:00 AM ET 01/07/2020
FLORHAM PARK, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. ( CLRB
CLRB, “...a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it has appointed Dr. Igor Grachev as Chief Medical Officer.
“I am excited to welcome Igor to our senior management team as Chief Medical Officer. Igor possesses outstanding academic training and a track record of professional success with highly relevant experiences including multiple global oncology drug approvals ,” said Jim Caruso, CEO of Cellectar. “We look forward to his leadership as we advance our pipeline of assets and work towards fully developing the potential of CLR 131.”
Igor Grachev, M.D., Ph.D., brings nearly 20 years of industry experience to Cellectar having led clinical development programs at both multinational pharmaceutical and biotech organizations. He served as Global Development Leader and Head of Innovative Clinical Trials Initiative, R&D for TEVA Branded Specialty Pharmaceuticals, where he was responsible for the development, execution and management of clinical programs worldwide across all phases of clinical research, achieving regulatory approvals in multiple countries. Dr. Grachev also had clinical development and medical affairs leadership roles at GE Healthcare, Novartis, GSK, Merck, Schering Plough, Sanofi-”
AND WHY GIVE HIM A 80,000 common shares stock option as shown in a subsequent SEC filing regarding a Power of Attorney filing for 4 people to make SEC Form 4 STOCK TRANSACTION notices for him?
SOMETHING IMPORTANT IS ABOUT TO HAPPEN, MAYBE NEXT SUNDAY?
Still lining their FDA ducks up:
Cellectar Biosciences Gets Orphan Drug Designation for Lymphona Treatment
BY Dow Jones & Company, Inc.
— 8:46 AM ET 01/06/2020
Cellectar Biosciences Inc. (CLRB) said Monday the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation to CLR 131 in lymphoplasmacytic lymphoma.
The company said CLR 131 is its lead Phospholipid Drug Conjugate product candidate currently in a Phase 2 clinical study in relapsed or refractory select B-cell lymphomas, including lymphoplasmacytic lymphoma.
Cellectar said CLR 131 has previously been granted Orphan Drug designation for the treatment of multiple myeloma by both the U.S. and the European Commission and Rare Pediatric Disease and Orphan Drug designations for the treatments of neuroblastoma, rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma.
Cellectar shares were up 9% to $2.50 premarket.
January promised data release? January 13-15, 2020?
Cellectar Biosciences to Present at Biotech Showcase 2020
BY GlobeNewswire
— 8:00 AM ET 12/19/2019
FLORHAM PARK, N.J., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences ( CLRB
Loading...
Loading...
), Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and chief executive officer of Cellectar Biosciences ( CLRB) will present a company overview at the Biotech Showcase on Monday, January 13, 2020 at 10:30 am Pacific Time. The conference will be held at the Hilton San Francisco Union Square on January 13-15, 2020.
A live and archived webcast of Mr. Caruso’s presentation will be available in the Investors section of the company’s website.
I don't believe anything this company puts out.
20 people in clinical trial and to more than double:
“Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study
BY GlobeNewswire
— 8:00 AM ET 12/16/2019
30% overall response rate seen with an average progression free survival of 4.5 months and an acceptable and expected safety profile
Additional data in patients receiving higher fractionated doses of CLR 131 anticipated in January
FLORHAM PARK, N.J., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences ( CLRB
Loading...
Loading...
), Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced summary data from 20 patients receiving a single dose of CLR 131 in its Phase 2 CLOVER-1 trial in select relapsed/refractory (RR) B-cell malignancies. The company had previously announced data from 10 multiple myeloma patients receiving a single dose of CLR 131 in February 2019, which showed a 30% overall response rate (ORR).
The Phase 2 CLOVER-1 study is designed to identify a safe and efficacious dose and regimen to be used in a pivotal study for select hematologic indications. The 20 evaluated patients, included 10 subjects with relapsed/refractory multiple myeloma, and 10 with relapsed/refractory B-cell lymphoma. The median age was 71 (range 52-82), including 7 females and 13 males, with a median of 6 prior systemic therapies for multiple myeloma and 4 for patients with lymphoma. Eight patients had prior autologous stem cell transplant therapy. Data from these 20 patients showed a 30% ORR, a 75% clinical benefit rate, an average progression free survival of 4.5 months and an acceptable and expected safety profile.
“The 30% ORR seen suggests that CLR 131 treatment at the single 25 mCi/m2 bolus dose may have activity in these heavily pre-treated patients,” said James Caruso, president and CEO of Cellectar Biosciences ( CLRB
Loading...
Loading...
). “We recently presented data at ASH on 19 patients with relapsed, refractory multiple myeloma, which showed improved efficacy and safety with fractionated doses vs. the single bolus dose, and patients receiving a fractionated dose of 37.5mCi showed a 50% ORR. As background, recently approved drugs for this indication have demonstrated approximate ORRs of 25% in a similar patient population and up to 29% as a third line treatment. We plan to provide additional data in patients who are receiving higher fractionated doses of CLR 131 in January.”
The primary adverse events (AEs) seen were cytopenias, including thrombocytopenia, anemia, neutropenia, and decreased white blood cell count. The hematologic AEs were expected, manageable and followed a predictable timeline to nadir (average 49 days) and subsequent recovery (average 16 days post nadir). Patients with disease in the bone marrow experienced more cytopenias than did patients with no detectable disease in the bone marrow. All patients recovered from the cytopenias.”
TWO PEOPLE??
Sunofwolf, you need to research more as studies and trials progress. The news release below mentions dozens and dozens of patients in past and near future clinical trials and the clearly stated prospect of HIGH dosing of CLR131 which can safely lead to much higher “overall response rates” (ORR).
Price has been creeping up the last few weeks in anticipation of more favorable data promised below in coming weeks:
“...FLORHAM PARK, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences (CLRB), Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the presentation of fractionated dosing data in 19 patients with relapsed/refractory multiple myeloma. Dr. Sikander Ailawadhi, M.D., Associate Professor, Division of Hematology/Oncology at Mayo Clinic Florida, presented the data in an oral presentation at the 61st Annual American Society of Hematology (ASH) meeting.
Dr. Ailawadhi’s presentation highlighted results from 19 patients with relapsed/refractory multiple myeloma from Cellectar’s Phase 1 and Phase 2 CLOVER-1 trial collected prior to July 30, 2019. The data from the oral presentation support prior literature and preclinical data showing that fractionated dosing provides an enhancement of efficacy and safety while reducing adverse events. The patients presented received one of 3 dose levels: a single bolus dose of 31.25 mCi/m2 or a fractionated dose of 31.25 mCi/m2 or a higher fractionated dose of 37.5 mCi/m2 of CLR 131. The fractionated 37.5 mCi/m2 dose of CLR 131 represents the greatest amount of drug administered to date in the Phase 2 CLOVER-1 trial.
The overall response rate (ORR) for all multiple myeloma patients across the 3 dose cohorts was 31.3% and a 100% disease control rate. Patients receiving the higher fractionated 37.5 mCi/m2 dose demonstrated a 50% ORR with the remaining 50% having minimal responses (greater than a 25% reduction in the surrogate marker of efficacy).
The patients presented had received a median of 4 prior systemic therapies (range 2-13), had a median age of 69 (range 51-83), including 8 females and 11 males and 80% of the patients in the 37.5 mCi/m2 cohort were either quad or penta-refractory, and all were refractory to [img]daratumumab.
These data showing a 50% overall response rate in a cohort of heavily pretreated multiple myeloma patients and a 31.3% overall response rate in all dose levels presented is impressive,” said Dr. Ailawadhi. “CLR 131 continued to demonstrate a good safety profile with limited off-target effects and the fractionated dosing of CLR 131 showed improved tolerability versus single bolus dosing. While these doses demonstrate beneficial activity, there is the potential that a second cycle or further fractionation could further enhance both efficacy and tolerability.”
The primary adverse events (AEs) at all dosing levels were cytopenias and included thrombocytopenia, anemia, and neutropenia. The hematologic AEs were expected, manageable and followed a predictable timeline to nadir (average 40 days) and subsequent recovery (average 17 days post nadir). The demonstrated recovery post nadir for CLR 131 compared favorably to other similar radiotherapeutic drugs, such as Bexxar, which requires on average 90 days for recovery post nadir.
“These results showed excellent safety with limited off-target effects and improved tolerability compared to our single bolus dosing. With the overall activity observed with CLR 131 to date and efficacy signals across all doses and especially at the fractionated dosing level of 37.5 mCi/m2, we remain optimistic about the potential for continued enhancement of efficacy and safety with fractionated dosing,” said Jim Caruso, president and CEO of Cellectar. “We anticipate announcing additional data in the coming weeks in patients receiving single bolus and fractionated dosing from our Phase 2 CLOVER-1 trial, in which we have enrolled approximately 50 patients. ”
A copy of the presentation deck can be accessed on the Posters and Publications section of the Cellectar website.
About the Phase 2 CLOVER-1 Trial
CLOVER-1 is a Phase 2 study of CLR 131 being conducted in approximately 10 leading cancer centers in the United States in patients with relapsed or refractory B-cell hematologic cancers. The hematologic cancers being studied in the trial include multiple myeloma (MM), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL).
The study will enroll up to 80 patients. Its primary endpoint is clinical benefit response (CBR), with additional endpoints of overall response rate (ORR), progression free survival (PFS), median overall survival (OS) and other markers of efficacy following a fractionated dose of 37.5mCi/m2 of CLR 131 administered in two 30-minute infusions of 18.75mCi/m2 of CLR 131 administered on day 1 and day 7 (± 1), with the option for a second dose cycle approximately 75-180 days later. The company expects to report topline data in 2019.
Cellectar was awarded approximately $2 million in non-dilutive grant funding from the National Cancer Institute to help fund the trial. More information about the trial, including eligibility requirements, can be found at www.clinicaltrials.gov, reference NCT02952508.
About the Phase 1 R/R MM Trial
The Phase 1 multicenter, open-label, dose-escalation study is designed to evaluate the safety and tolerability of CLR 131 administered as a 30-minute IV infusion, either as a single bolus dose or as two fractionated doses, in patients with R/R MM. All doses to date have been deemed safe and well tolerated by an independent Data Monitoring Committee (DMC). Based on the data and the recommendation of the DMC, the Company is enrolling a Cohort 7 where patients will receive 40mCi/m2 fractionated dose of CLR 131.
About CLR 131
CLR 131 is a small-molecule, targeted Phospholipid Drug Conjugate™ (PDC) designed to deliver cytotoxic radiation directly to cancer cells, while limiting exposure to healthy cells. CLR 131 is the company’s lead product candidate and is currently being evaluated in a Phase 2 study in B-cell lymphomas, and two Phase 1 dose-escalating clinical studies, one in multiple myeloma and one in pediatric solid tumors and lymphoma. CLR 131 was granted Orphan Drug designation for the treatment of multiple myeloma by both the U.S. and the European Commission, and was granted U.S. Orphan Drug and Rare Pediatric Disease designations for the treatment of neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma.
About Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences (CLRB) is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development (R&D) collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug ConjugateTM (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.
The company’s lead PDC therapeutic, CLR 131, is currently in three clinical studies – a Phase 2 study, and two Phase 1 studies. The Phase 2 clinical study (CLOVER-1) is in relapsed/refractory (R/R) B-cell malignancies, including multiple myeloma (MM), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL). The company is also conducting a Phase 1 dose escalation study in patients with R/R multiple myeloma (MM) and a Phase 1 study in pediatric solid tumors and lymphoma.
The company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900) and several partnered PDC assets.
Contacts
Investors:
Monique Kosse
Managing Director
LifeSci Advisors
212-915-3820
monique@lifesciadvisors.com
Image: CLRLB.png
Source: Cellectar Biosciences (CLRB)
MORE CLRB NEWS
CLRB ASH Presentation 12/7/19 Abstract:
As posted by ASH:
...Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Discrasias
Hematology Disease Topics & Pathways:
Adult, B-Cell Lymphoma, Technology and Procedures, Study Population, radiation
Saturday, December 7, 2019: 10:45 AM
Hall E1, Level 2 (Orange County Convention Center)
Sikander Ailawadhi, MD1, Patrick J. Stiff, MD2, Emad Ibrahim, MBBCh, MD3, Anusha Vallurupalli, MBBS4, Elizabeth H. Cull, MD5, Damian J. Green, MD6, Kate Oliver, BS7* and Jarrod Longcor8*
1Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL
2Loyola University Chicago Stritch School of Medicine, Maywood, IL
3Redlands Community Hospital, Redlands, CA
4University of Kansas Cancer Center, Westwood, KS
5Cancer Institute, Prisma Health, Piedmont, SC
6Fred Hutchinson Cancer Research Center, Seattle, WA
7Cellectar Biosciences, Madison, WI
8Cellectar Biosciences, Florham Park, NJ
Background: CLR 131 is a novel targeted radiotherapeutic that exploits the selective uptake and retention of phospholipid ethers (PLEs) by malignant cells. Based on initial preclinical and clinical experience and the radiosensitivity of MM, fractionated dosing of CLR 131 is being examined in RRMM in a Phase 1 trial (NCT02278315) and a Phase 2 trial, CLOVER-1 (NCT02952508).
Methods: Both the Phase 1 and Phase 2 trials of CLR 131 aim to determine efficacy and safety in RRMM. Eligibility criteria include progressive or relapsed MM that is refractory to at least 1 proteasome inhibitor (PI) and 1 immunomodulatory (IMiD) drug with no upper limit to the number of prior lines of therapy. Prior autologous stem cell transplant (ASCT) and external beam radiation therapy are allowed (< 20% of total marrow irradiated). The Phase 1 trial was a single and fractionated ascending dose escalation safety study and the Phase 2 trial is evaluating 3 doses: a bolus dose and 2 fractionated doses. The fractionated doses of CLR 131 included infusion of either 31.25 mCi/m2 CLR 131 or 37.5 mCi/m2 CLR 131 (administered as 15.625 mCi/m2 or 18.75 mCi/m2, respectively, on day 1 and day 7 (± 1 day)) administered as a 30-minute intravenous infusion is reported here. Adverse events (AEs) are graded by NCI-CTCAE v4.03. Responses were determined using IMWG criteria as assessed by the investigator.
Results: As of 30Jul2019, 10 subjects have received fractionated 31.25 mCi/m2 and 6 subjects fractionated 37.5 mCi/m2 CLR 131. In addition, 1 subject was scheduled to receive fractionated 37.5 mCi/m2 CLR 131 but died due to progressive disease prior to administration of the second dose; this subject is not included in the analyses below as they did not receive both fractionated doses. There is no upper age limit for enrollment and the median age for the 16 RRMM patients was 71 (range 51-83), including 6 females and 10 males with a median of 4 prior therapies (range 2 to 13). Seven patients had prior ASCT.
CLR 131 demonstrated 100% disease control rate in subjects receiving either fractionated dose of CLR 131. The overall response rate (ORR) in the fractionated 37.5 mCi/m2 cohort is 50%. Three subjects in the cohort experienced a partial responses (PR), median time to response 43 days, and the other three had minimal responses (MR) with an average 39% reduction in m-protein. In this cohort, 80% of the subjects were either quad- or penta-refractory; all 80% were refractory to daratumumab. There were two subjects in the 31.25 mCi/m2 cohort with non-secretory disease and their status was followed by FDG-PET imaging. Both have been excluded from the evaluation of efficacy as their disease does not meet with IMWG criteria for response. No patients in this cohort achieved a PR or better however a majority of the subjects experienced a minimal response. The primary AEs include thrombocytopenia, anemia, neutropenia, and fatigue (Table 2). The hematologic AEs were expected, manageable and followed a predictable timeline to nadir (average. 40 days) and subsequent recovery (average 17 days post nadir).
Conclusions: CLR 131 is a unique, first in class targeted radiotherapeutic for RRMM. Preliminary data for CLR 131 administered as a fractionated dose shows an acceptable and expected safety profile in this patient population. Fractionated dosing at 37.5 mCi/m2 has shown an efficacy signal and has been adopted as the standard for CLR 131 dosing in ongoing and future trials. Dose escalation to determine the highest tolerated dose is ongoing in the Phase 1 study and is currently examining a fractionated infusion of 40 mCi/m2 administered as 20 mCi/m2 CLR 131 on day 1 and day 7 (± 1 day). [/] Based upon these data enrollment to the fractionated 37.5 mCi/m2 cohort of the Phase 2 trial continues...”
Link: https://ash.confex.com/ash/2019/webprogram/Paper131014.html
Above $2 where I belongs
For now but where is the promised Q4 data on clinical trials at higher CLR131 dosing?
Here comes $2.00 per share,
...Regardless of the negative know nothings with unsubstantiated assertions.
a whole two people-this is just nonsense!
I thought THIS news was imminent,
referring to the 3rd and 4th paragraphs below from a September 2019 CLRB press release.
But yes this week was too soon:
“... The poster, entitled: “CLR 131 Demonstrates High Rate of Activity in a Phase 1, Dose Escalation Study in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)” highlights data from 4 subjects in Cohort 6 who received a fractionated dose of 37.5 mCi/m2. Subjects in this cohort achieved a 50% overall response rate, with two subjects achieving a partial response and two subjects achieving minimal responses (39% and 48% reduction in M protein). CLR 131 was deemed safe and tolerated in all subjects with cytopenias being the only reported treatment emergent adverse events of grade 3 or higher. The majority (75%) of the subjects had high risk cytogenetics where median bone marrow plasma cell involvement was 25%. Patients’ median age was 72.5 and averaged 5 prior systemic therapies, with one patient being dual class refractory, one being quad-refractory, and two being penta-refractory.
The Phase 1 study employs the International Myeloma Working Group (IMWG) criteria for measuring responses. The IMWG defines a partial response as a 50% reduction in the marker of disease and a minimal response as a 25% to 49.9% reduction.
“Cohort 6’s overall response rate of 50% with 100% disease control in highly chemo-refractory elderly patients highlights CLR 131’s potential as a first-in-class targeted radiotherapeutic for relapsed or refractory multiple myeloma. We saw an encouraging dose response compared to prior cohorts and CLR 131 continues to demonstrate a favorable safety profile,” said James Caruso, president and CEO of Cellectar. “We have progressed to a higher 40 mCi/m2 fractionated dose Cohort 7 with data expected in Q4 2019.
Additionally, based on the positive results from Cohort 6, we are now allowed to use the 37.5 mCi/m2 dosing level in our ongoing Phase 2 (CLOVER-1) study evaluating CLR 131 in patients with relapsed/refractory (R/R) B-cell malignancies and expect data from the Phase 2 trial in Q4 2019.”
IT WILL BE MOST INTERESTING TO SEE IF THE ORR IS CLOSER TO 75% WITH THE HIGHER DOSING. IF SO, CLRB AND CLRBZ WILL SKY ROCKET UP, UP AND AWAY!
maybe to soon, goes up fast then news come out then move's back down.
Whale was getting full,
So I sold all my CLRB common shares.
No press release to support the spike.
We have a big whale buyer,
and once again you have to ask WHY. Why are deep pockets interested in this previously lackluster stock/company?
Unless we have a press release soon from CLRB, there are only two explanations:
1. Market price manipulation by the company or 3rd party to screw legitimate investors/traders;
2. A fund thinks that based what is already on the table, i.e. publicly disclosed, this company is undervalued and CLRB IS about to prove it.
A POSITIVE PRESS RELEASE TODAY OR TOMORROW FROM CLRB WOULD ALSO EXPLAIN THE PRICE APPRECIATION OF THIS MISERABLE PERFORMER OVER THE LAST YEAR.
SO WHAT IS THE EXPLANATION?????
A close in the $1.60’s would be validation,
With volume over a million shares.
A close in the $1.20’s would be Wolf food. LOL
Selling the spike has stopped for now,
Interesting. Weak hands waiting to know if good news is imminent before taking it down to $1.10.
Time will tell... but nice Fibonacci retrace so far:
Back down (this morning) 38.2 % more or less.
stupid long term investors stock is almost worthless do to the constant reversing of the stock- NASD is allowing companies cheat investors by reversing the stock to collect fee's from these companies.
insiders selling the stock back and forth to make it look like its trading.
there aren't any studies at all being done,this is a brief case company only exist on phony reports. Go to New jersey to see where all the dough is being spent.
the proof is the share price, once it goes below a $1, CLRB will make up another story or reverse the stock for the 20th time.
Ok, Mr. Negative,
Verifiably prove there are only two people in CLR 131 clinical trials.
Put up, or shut up the defamatory libel.
this company is a fraud, they are only selling worthless shares to suckers and a drugs that don't work. 2 people taking drugs is not a study at all.
seeing how there is so few people taking these drugs-the results have zero meaning to anyone. The Ceo is just conning investors so he can get a big salary and fancy office,the founders have long left and the company is totally Brain Dead. Why is is company on nasd small caps? Is it just because they pay NASD a fee- Yes it is NASD listing means nothing.
Never been to the office, they spent a lot of money on it and are hiding how much it cost. I have zero confidence in this company, I think a lot of the claims of success are phony.
Sun, have you been to the the NJ office? Have you gone inside?
Lots of selling and zero buying, who wants to pay for the CEO fancy office in NJ, company has never made 2 cents except from stupid investors.
Bubble, bubble, toil & trouble,
https://ih.advfn.com/stock-market/NASDAQ/cellectar-biosciences-CLRB/stock-news/81029249/current-report-filing-8-k#TM1921486D1_EX99-1_HTM
One of these days, “Wolfe”, one of these days: to the moon sonny.
this stock is worthless and should even be listed on NASD small caps just go to show how much cheating goes on with this company-garbage junk!
ot buying stocks any more-All I do is lose to thief's like this CEO is. Never seen anything here but fake stories,.
ROFLMAO...all so true. Factual & refreshing!
Well, we will know soon enough, with Ph1 7th cohort result in MM and 4 ph2 results in B Cell Malignancies all due in Q4 2019. Good luck with your short
this company does nothing but dilution and is a shareholders nightmare. Comes up with nothing but fake products that go no where. makes zero money except from stupid investors.
What i like most about clr 131 technology is that it can make radiooncology usable also in metastatic setting so to expand its market by 10 times imo. And that pdc technology potentially applies to all oncology drugs making them safer and more effective
This company is not a joke nothing will ever
stop its progress, all be it slow and deliberate like any good biotech.
https://www.cellectar.com/product-pipeline
The stock is another issue in the meantime.
People seem to forget that common stock’s purpose, for the company, is to raise revenue to build its business after start-up. When a company succeeds making profits, common stock’s purpose for shareholders is to make money as owners. The younger generations seem to think if it is not a microwave oven, it is not an oven.
Warren Buffett prefers old fashioned ovens for good food...that or cheese burgers and coke.
This company is a joke nothing will ever be developed here ever!
I Today’s 9/30/19 CLRB stock price says
that the weekend’s European presentation was “underwhelming” as compared to expectations.
Now I need to wait and see how TWO IV doses at higher CLR 131 levels in the Phase 2 Clover study helps DLBCL patients as distinguished from these results revealed over the weekend:
“...The oral presentation, entitled: “Interim Evaluation of a Targeted Radiotherapeutic, CLR 131, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients (R/R DLBCL),” featured data from 6 subjects who received a single 30-minute intravenous (IV) dose of 25mCi/m2 of CLR 131. Data showed durable responses, including a 33% overall response rate (ORR), a 16.6% complete response rate (CR) and a 50% clinical benefit rate (CBR). All patients enrolled in the study received an average of 3 prior lines of systemic therapy, 5 of 6 patients were refractory to at least one prior line of therapy. Importantly, CLR 131 showed activity against both germinal center and activated DLBCL. In a patient for whom cytogenetics was available, CLR 131 showed activity against c-Myc and BCL-2 mutation (single & dual-hit) positive patients. As required by the Lugano Criteria for Response, the patient who experienced a CR had a total reduction in tumor volume of greater than 99% and continues to be a CR at 510+ days post dosing. This patient was refractory to two prior treatment lines, which included the combination regimen RICE.
Analysis of dosing showed that the disease control rate and progression free survival were markedly improved in patients receiving a dosing ratio of 1.2% or greater (drug to tumor volume) versus those receiving below a 1.2% dosing ratio. Finally, the most frequent adverse events (AE) in DLBCL patients were consistent with prior studies of CLR 131; the majority of AEs being hematologic in nature and predominately Grades 1 and 2.
“The data presented show an encouraging overall response rate including a complete response at the time of the interim assessment after a single 30-minute IV dose of 25mCi/m2 of CLR 131. We remain optimistic that CLR 131 has the potential to provide a meaningful treatment option for a variety of lymphoma patients and look forward to reporting additional data from this Phase 2 CLOVER-1 study in 2019,” said James Caruso, president and CEO of Cellectar. “The study remains ongoing and, based on this cohort and additional data from an ongoing dose escalation Phase 1 study, patients in the Phase 2 CLOVER-1 study are now receiving a higher 37.50 mCi/m2 fractionated dose administered in two 30-minute infusions of 18.75mCi/m2.”
CLRB NEEDS A MUCH HIGHER OVER ALL RESPONSE RATE (ORR), AGAINST ALL THE CANCER TYPES, OR A FEW OF THEM, BEFORE THE STOCK PRICE CAN HIT $5+ or $10+ price per share AND PATIENTS CAN TRULY BENEFIT!
TO BE CLEAR, AN ORR OF OVER 50% will be needed! I prefer 75%.
https://finance.yahoo.com/news/cellectar-announces-oral-presentation-european-120000188.html
Are they showing updated interim results tomorrow?
I stand corrected, staccani,
I misread the summary below which has accompanied the last few PR’s.
It says there are “three” clinical studies, one a phase 2 and two in phase 1, there are no phase 3 trials that have started. Sorry to post an inaccuracy.
PR SUMMARY LANGUAGE:
“...The company’s lead PDC therapeutic, CLR 131, is currently in three clinical studies – a Phase 2 study, and two Phase 1 studies. The Phase 2 clinical study (CLOVER-1) is in relapsed/refractory (R/R) B-cell malignancies, including multiple myeloma (MM), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL). The company is also conducting a Phase 1 dose escalation study in patients with R/R multiple myeloma (MM) and a Phase 1 study in pediatric solid tumors and lymphoma...”
Ph2a is still ongping ... on Saturday they should present ph2a interim results for DLBCL.. Starting of PH3 seems a bit premature.. how do you come to such conclusion?
Maybe, but the REAL NEWS in a few days
should be about non-Hodgkin lymphoma (DLBCL) results in the PHASE 3 clinical trials of CLRB’s CLR-131:
Diffuse large B-cell lymphoma is a cancer of B cells, a type of white blood cell responsible for producing antibodies. It is the most common type of non-Hodgkin lymphoma among adults,[1] with an annual incidence of 7–8 cases per 100,000 people per year in the USA and the UK.[2][3] This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age,[3] though it can also occur in children and young adults in rare cases.[4] DLBCL is an aggressive tumor which can arise in virtually any part of the body,[5] and the first sign of this illness is typically the observation of a rapidly growing mass, sometimes associated with B symptoms—fever, weight loss, and night sweats.[6]
This weekend could be the stage for news, after today’s announcement that CLR-131 was granted orphan drug designation by the European Commission:
Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019
BY GlobeNewswire
— 8:00 AM ET 09/10/2019
FLORHAM PARK, N.J., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences (CLRB), Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced an oral presentation at the upcoming European Society for Medical Oncology ESMO Congress 2019 being held in Barcelona, Spain from September 27 – October 1, 2019.
The presentation will focus on the nature of the patient population and the activity of CLR 131 in these heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Followers
|
122
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8169
|
Created
|
08/01/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |